Your browser doesn't support javascript.
loading
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
Ott, P A; Piha-Paul, S A; Munster, P; Pishvaian, M J; van Brummelen, E M J; Cohen, R B; Gomez-Roca, C; Ejadi, S; Stein, M; Chan, E; Simonelli, M; Morosky, A; Saraf, S; Emancipator, K; Koshiji, M; Bennouna, J.
Afiliación
  • Ott PA; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, USA.
  • Piha-Paul SA; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Munster P; Department of Medicine (Hematology/Oncology), Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA.
  • Pishvaian MJ; Department of Hematology/Oncology, Georgetown University, Washington DC, USA.
  • van Brummelen EMJ; Department of Molecular Pathology & Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Cohen RB; Department of Medicine, University of Pennsylvania, Philadelphia, USA.
  • Gomez-Roca C; Clinical Research Unit, Institut Claudius Regaud and Institut Universitaire du Cancer-Oncopole, Toulouse, France.
  • Ejadi S; Department of Medical Oncology, Virginia G. Piper Cancer Center, Scottsdale, USA.
  • Stein M; Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA.
  • Chan E; Department of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center, Nashville, USA.
  • Simonelli M; Department of Medical Oncology and Hematology, Humanitas Cancer Center, Rozzano, Italy.
  • Morosky A; Department of Clinical Oncology, Merck & Co, Inc., Kenilworth, USA.
  • Saraf S; Department of Clinical Oncology, Merck & Co, Inc., Kenilworth, USA.
  • Emancipator K; Department of Clinical Oncology, Merck & Co, Inc., Kenilworth, USA.
  • Koshiji M; Department of Clinical Oncology, Merck & Co, Inc., Kenilworth, USA.
  • Bennouna J; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.
Ann Oncol ; 28(5): 1036-1041, 2017 05 01.
Article en En | MEDLINE | ID: mdl-28453692
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias del Ano / Carcinoma de Células Escamosas / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias del Ano / Carcinoma de Células Escamosas / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos